{"title": "PDF", "author": "PDF", "url": "https://panel.aam.org.ar/img_up/11072022.8.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "Revista  Argentina  de  Microbiolog\u00eda  54  (2022)  120- - -124\nwww.elsevier.es/ramR  E  V  I  S  T  A  A  R  G  E  N  T  I  N  A  D  E\nMICROBIOLOG\u00cdA\nBRIEF  REPORT\nAntibiotic  susceptibility  and  fosfomycin  resistance\ncharacterization  in  a  cohort  of  children  older  than  6\nyears of  age  with  urinary  tract  infection\nVirginia  Garcia-Fulgueirasa,1,  Leticia  Caiataa,  Ines  Badoa,  Gustavo  Giachettob,\nLuciana\n Robinoa,\u2217,1\naDepartamento  de  Bacteriolog\u00eda  y  Virolog\u00eda,  Instituto  de  Higiene,  Facultad  de  Medicina,  Universidad  de  la  Rep\u00fablica,\nMontevideo, Uruguay\nbDepartamento  de  Pediatr\u00eda,  Asociaci\u00f3n  Espa\u02dcnola,  Montevideo,  Uruguay\nReceived 26  November  2020;  accepted  26  April  2021\nAvailable online  19  June  2021\nKEYWORDS\nEscherichia coli;\nFosfomycinresistance;Urinary tract\ninfection;fosA3 ;\nChildrenAbstract Fosfomycin  tromethamol  (FT)  was  reintroduced  as  an  option  for  the  treatment  of\nlow urinary  tract  infection  (UTI)  in  children.  In  this  study,  we  described  the  antibiotic  sensitivity\nand mechanisms  of  resistance  to  fosfomycin  in  isolates  from  children  older  than  6  years  with\nUTI. Urine  culture  and  antibiotic  susceptibility  study  were  performed.  In  fosfomycin  resistant\nstrains, PCR  for  fos,  blaCTX-M was  performed  followed  by  classi\ufb01cation  by  phylogenetic  group\nand sequencetyping.  Escherichia  coli  was  the  most  frequent  etiological  agent  (89.2%).  The\nsusceptibility percentages  were:  fosfomycin  97.9%;  amoxicillin-clavulanate  92.7%;  cefuroxime\nand ceftriaxone  99%;  nitrofurantoin  94.4%.  An  E.  coli  strain  (ST69,  phylogenetic  group  D)  was\nresistant to  fosfomycin  (MIC  256  mg/l)  and  carried  the  blaCTX-M-14 and  fosA3  genes  in  a  45  kb\nIncN-type plasmid.  This  is  the  \ufb01rst  report  of  E.  coli  ST69  with  blaCTX-M-14 /fosA3  of  human  origin.\n\u00a9 2021  Asociaci \u00b4on  Argentina  de  Microbiolog \u00b4\u0131a.  Published  by  Elsevier  Espa\u02dcna,  S.L.U.  This  is  an\nopen access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-\nnc-nd/4.0/ ).\nPALABRAS  CLAVE\nEscherichia  coli;\nResistencia a\nfosfomicina;Infecci\u00f3n urinaria;\nfosA3 ;\nNi\u02dcnosSensibilidad antibi\u00f3tica  y  caracterizaci\u00f3n  de  la  resistencia  a  fosfomicina  en  una\ncohorte de  ni\u02dcnos  mayores  de  6  a\u02dcnos  con  infecci\u00f3n  urinaria\nResumen  La  fosfomicina-trometamol  (FT)  se  reintrodujo  como  una  opci\u00f3n  para  el  tratamiento\nde la  infecci\u00f3n  del  tracto  urinario  (ITU)  baja  en  ni\u02dcnos.  En  este  estudio  describimos  la  sensibilidad\nantibi\u00f3tica y  los  mecanismos  de  resistencia  a  FT  en  aislamientos  de  ni\u02dcnos  mayores  de  6  a\u02dcnos\ncon ITU.  Se  realizaron  urocultivos  y  estudios  de  sensibilidad  antibi\u00f3tica.  En  las  cepas  resistentes\n\u2217Corresponding  author.\nE-mail address:  lurobino@gmail.com  (L.  Robino).\n1These  two  authors  share  the  senior  authorship  of  this  work.\nhttps://doi.org/10.1016/j.ram.2021.04.002\n0325-7541/\u00a9 2021  Asociaci \u00b4on  Argentina  de  Microbiolog \u00b4\u0131a.  Published  by  Elsevier  Espa\u02dcna,  S.L.U.  This  is  an  open  access  article  under  the  CC\nBY-NC-ND license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Revista  Argentina  de  Microbiolog\u00eda  54  (2022)  120- - -124\na  fosfomicina  se  realiz\u00f3  la  t\u00e9cnica  de  PCR  para  fos,  blaCTX-M,  y  su  identi\ufb01caci\u00f3n  seg\u00fan  su  grupo\n\ufb01logen\u00e9tico y  secuenciotipo.  Escherichia  coli  fue  el  agente  etiol\u00f3gico  m\u00e1s  frecuente  (89,2%).  Los\nporcentajes de  sensibilidad  fueron:  fosfomicina  97,9%;  amoxicilina-clavul\u00e1nico  92,7%;  cefurox-\nima y  ceftriaxona  99%;  nitrofuranto\u00edna  94,9%.  Una  cepa  de  E.  coli  (ST69,  grupo  \ufb01logen\u00e9tico  D)\nfue resistente a  fosfomicina  (CIM  256  mg/l)  y  portaba  los  genes  blaCTX-M-14 y  fosA3  en  un  pl\u00e1s-\nmido de  45  kb  del  tipo  IncN.  Este  es  el  primer  reporte  de  E.  coli  ST69  con  blaCTX-M-14 /fosA3  de\norigen humano.\n\u00a9 2021  Asociaci \u00b4on  Argentina  de  Microbiolog \u00b4\u0131a.  Publicado  por  Elsevier  Espa\u02dcna,  S.L.U.  Este  es  un\nart\u00b4\u0131culo Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-\nnc-nd/4.0/ ).\nFosfomycin  is  an  old  antibiotic  that  has  reemerged  as  a\nnew strategy  to  overcome  antibiotic  resistance.  Fosfomycin\nspectrum of  action  includes  gram-positive  (Staphylo-\ncoccus aureus ,  Enterococcus  spp.)  and  gram-negative\nbacteria (Enterobacterales , Pseudomonas  spp.),  including\nmulti-resistant microorganisms  such  as  extended-spectrum\nbeta-lactamase (ESBL)  and  carbapenemase  producers6.\nIts mechanism  of  action  is  cytosolic  inactivation  of  N-\nacetylglucosamine enolpyruvyl transferase (MurA),  which\nprevents the formation of N-acetylmuramic  acid  from\nN-acetylglucosamine and phosphoenolpyruvate, being  the\ninitial step of peptidoglycan  synthesis.  Fosfomycin  crosses\nthe bacterial wall using the  transport  system  glycerol-\n3-phosphate (GlpT) and the  transport  system  for  hexose\nphosphates (UhpT)6.\nThere are two presentations of  this  antibiotic,  fosfomycin\ndisodium (for parenteral use) and fosfomycin  trometamol\n(FT)  with  good  oral  bioavailability  and  only  indicated  for\nlower UTI8.\nThe increase  in  the  clinical  use  of  fosfomycin  has  led  to\nthe development  of  different  resistance  mechanisms,  par-\nticularly, when  used  as  monotherapy8.\nFosfomycin resistance  can  result  from  reduced  perme-\nability (mutations  in  the  chromosomal  glpT  and  uhpT  genes),\namino acid  mutations  in  the  active  site  of  the  MurA  target,\nand the  production  of  fosfomycin-inactivating  enzymes\n(fos genes).  Different  fosfomycin-modifying  enzymes  have\nbeen described.  FosA  (glutathione  S-transferase),  the\n\ufb01rst to  be  described,  is  a  metalloenzyme  transferred\nthrough plasmids  in  Enterobacterales .  The  FosA3  enzyme\nis the  most  commonly  identi\ufb01ed  FosA-like  determinant\nfound as  an  acquired  mechanism  in  Escherichia  coli6.  The\nfosA3 gene  is  usually  located  in  conjugative  plasmids  also\ncarrying CTX-M-type  ESBL-encoding  genes8,  and  related\nto different  plasmid  incompatibility  groups  (IncN,  IncF ,\nIncFII, IncI1,  among  others)2.  Other  fos  genes,  such  as\nfosA4 , fosA5 ,  and  fosA6  have  also  been  identi\ufb01ed  in  E.  coli,\nalthough less frequently8.  In  some  Enterobacterales  (i.e,\nSerratia marcescens , Klebsiella  spp.,  Enterobacter  spp.,\nKluyvera georgiana ) there  are  homologous  chromoso-\nmal fosA genes and these  isolates  can  present  reduced\nfosfomycin  susceptibility6.  Other  fosfomycin-modifying\nenzymes are  FosB  (in  gram-positive  bacteria),  FosX  (chro-\nmosomal enzyme  in  Listeria  monocytogenes )  and  FosC\n(in Pseudomonas  syringae ).  Kinases  that  cause  fosfomycindegradation  through  phosphorylation  (FomA  and  FomB)\nhave been  identi\ufb01ed  in  Streptomyces  spp8.\nIn relation  to  the  clinical  use  of  fosfomycin,  although\nit is  an  old  antibiotic,  the  experience  in  children  is\nscarce. Recently, a  review  of  fosfomycin  use  in  pedi-\natrics recommends  it  for  UTI  treatment,  osteomyelitis  (such\nas in  cases  caused  by  methicillin-resistant  S.  aureus ),\nand in  combination  for  multidrug-resistant  gram-negative\nbacilli in bacteremias (especially  enterobacteria  harboring\ncarbapenemases)1. In the  last  years,  FT  was  introduced  as\nan option for the  treatment  of  lower  UTI  in  children  older\nthan 6 years of  age  and  adults12.\nDespite the fact that fosfomycin  use  is  increasing,  suscep-\ntibility to FT is  not  routinely  tested  in  all  laboratories  and\nthere is sparse data available about  susceptibility  pro\ufb01les\nin E. coli isolates from  UTI  in  children.  Hereby  we  propose\nto describe the antibiotic susceptibility of  isolates  obtained\nfrom  urinary  tract  infections  in  children  older  than  6  years\nold, and  to  characterize  FT  resistance  mechanisms  involved\nin resistant  strains.\nChildren aged  6- - -14  years  old  with  UTI,  assisted  at  a\nhospital in  Uruguay  during  5/15/2018- - -8/15/2019,  were\nincluded. UTI  was  de\ufb01ned  as  the  presence  of  suggestive\nUTI clinical  symptoms  (dysuria,  increased  frequency  of  uri-\nnation, fever)  and  con\ufb01rmed  by  a  signi\ufb01cant  bacterial\ncount (1  \u00d7  105CFU/ml)  and  monomicrobial  growth  in  urine\nculture. Urine  culture,  bacterial  identi\ufb01cation  and  antibiotic\nsusceptibility were  assessed  by  automated  systems  either\nVitek\u00ae2  (bioMerieux,  Marcyl\u2019Etoile,  Francia,  ASTN250)  or\nPhoenix\u00ae(Becton  Dickinson  Diagnostics,  Sparks,  MD,  EEUU,\npanel BGN  448879)  and  results  were  interpreted  according\nto CLSI.4\nSusceptibility  to  fosfomycin  was  tested  by  disk  diffusion\n(200ug disc  OXOID\u00ae,  Hampshire  United  Kingdom),  in  accor-\ndance with  CLSI  guidelines4.  Unfortunately,  CLSI  breakpoints\nto fosfomycin  only  apply  to  E.  coli  urinary  tract  isolates,\nwhich makes the  study  dif\ufb01cult  for  other  Enterobacterales .\nIn this work, we  employed  the  susceptible  E.  coli  breakpoint\n\u226516 mm  for  fosfomycin  to  all  Enterobacterales .  For  resistant\nisolates, minimum inhibitory  concentration  was  determined\n(MIC) by agar dilution, using  Muller  Hinton  agar  (OXOID\u00ae,\nHampshire  United  Kingdom)  supplemented  with  glucose-6-\nphosphate (25  mg/l)4.\nPolymerase chain  reaction  (PCR)  for  fosA  and  fosA3\nwas performed  in  Fosfomycin-resistant  isolates10.  Isolates\n121V.  Garcia-Fulgueiras,  L.  Caiata,  I.  Bado  et  al.\nTable 1 Antibiotic  susceptibility  results  for  Enterobacterales  (data  exposed  as  susceptible  to  each  antibiotic).  Percentages  are\nexpressed for  E.  coli  isolates.\nAntibiotic  E.  coli  (n  =  255)  Proteus  mirabilis\n(n =  14)Klebsiella\npneumoniae  (n  =  7)\nAmpicillin  203  (79.6%)  13  0\nAmoxicillin-clavulanate 234  (91.8%)  14  7\nTrimethoprim-sulfamethoxazole 187  (73.3%)  13  7\nCefazolin 247  (96.9%)  14  7\nCefuroxime 253  (99.2%)  14  7\nCeftriaxone 253  (99.2%)  14  7\nCipro\ufb02oxacin 236 (92.5%) 13 7\nGentamicin 247  (96.8%) 14  7\nNitrofurantoin 254  (99.6%) 0 6\nFosfomycin 254  (99.6%)  14  7\nharboring  a  fosfomycin  resistant  gene  were  further  cha-\nracterized by  PCR  for  extended  spectrum  beta-lactamases\nof the  CTX-M  family:  bla CTX-M-group-1 ,  bla CTX-M-group-2 ,\nbla CTX-M-group-3 ,  bla CTX-M-group-4 ,  bla CTX-M-group-25 and  trans-\nferable quinolone  resistance  genes:  qnrA ,  B,  C,  D,  S,  VC\nand aac(6/prime)Ib-cr10.\nPositive results  were  con\ufb01rmed  by  Sanger  sequencing,\nand sequences  were  analyzed  using  the  BLASTn  database\n(https://blast.ncbi.nlm.nih.gov ).\nTheir phylogenetic  group  was  characterized  according  to\nClermont et  al.3,  and  sequence  type  (ST)  classi\ufb01cation  was\ndone following  the  scheme  to  identify  major  E.  coli  ST  caus-\ning urinary  tract  and  bloodstream  infections  (ST69,  73,  95,\nand 131) proposed  by  Doumith  et  al7.\nMobility of resistance genes  was  analyzed  by  conju-\ngation assays using  rifampicin-resistant  E.  coli  J53-2  as\nrecipient9. Transconjugants  were  selected  on  Luria  Bertani\nagar plates supplemented with  fosfomycin  (1  mg/l)  and\nglucose-6-phosphate (25 mg/l) plus rifampicin (150  mg/l).\nIncompatibility  groups and toxin- - -antitoxin mechanisms\n(i.e.: addiction systems) were detected by  PCR  using  donor\nand transconjugant genomic DNA as template  as  reported\npreviously9.\nPlasmid size  was  estimated  in  donor  strain  and  transcon-\njugant by  treatment  with  S1  nuclease  followed  by\npulsed-\ufb01eld gel  electrophoresis  (PFGE)9.\nClinical data  of  patients  with  UTI  caused  by  fosfomycin-\nresistant bacteria  were  collected  by  revision  of  medical\nrecords. Variables  collected  were  age,  sex,  symptoms  and\nsigns, urine  exam  results,  whether  it  was  the  \ufb01rst  episode  of\nUTI or  recurrence,  presence  of  morphological  or  functional\nabnormalities of  the  urinary  tract  and  antibiotic  consump-\ntion in  the  last  6  months.  The  study  was  approved  by  the\nethics committee  and  board  of  directors.\nFrom May  2018  to  August  2019,  286  urine  cultures  with\nsigni\ufb01cant growth  (1  \u00d7  105CFU/ml)  were  obtained.  E.  coli\nwas the  most  frequent  etiological  agent  in  255  urine  cultures\n(89.2%), followed  by  P.  mirabilis  in  14  (4.9%),  K.  pneumoniae\nin 7  (2.5%),  Staphylococcus  saprophyticus  in  5  (1.7%),  and\nothers in  5  (1.7%).\nAntibiotic susceptibility  for  the  total  of  isolates  was\n(susceptible results):  280  to  fosfomycin  (97.9%),  158  to\nampicillin (55.2%),  265  to  amoxicillin-clavulanate  (92.7%),279  to  cefazolin  (97.6%),  283  to  cefuroxime  and  ceftriax-\none (99%),  266  to  cipro\ufb02oxacin  (93%),  270  to  nitrofurantoin\n(94.4%), 215  to  trimethoprim-sulfamethoxazole  (75.2%)  and\n279 to  gentamicin  (97.6%).  Six  isolates  were  resistant  to\nfosfomycin (5  S.  saprophyticus  with  fosfomycin  natural\nresistance and  1  E.  coli).  Antibiotic  susceptibility  results\nfor main  enterobacteria  species  are  shown  in  Table  1.\nE. coli  showed  high  susceptibility  levels  (above  90%)  to\namoxicillin-clavulanate, cephalosporins,  \ufb02uoroquinolones,\naminoglycosides, nitrofurantoin  and  fosfomycin.\nESBLs were  phenotypically  detected  in  2  E.  coli  isolates,\nbut only  one  isolate  (Ec870)  was  resistant  to  (Table  1  and  2).\nEc870 was  obtained  from  the  urine  of  a  6-year  old  girl\nwith dysuria and  abdominal  pain.  This  was  her  \ufb01fth  UTI\nepisode in the last  2  years,  all  caused  by  E.  coli  isolates\nwith the same  resistance  pro\ufb01le  (only  resistant  to  ampi-\ncillin and trimethoprim-sulfamethoxazole). In  the  last  6\nmonths she had received  multiple  antibiotic  treatments  with\namoxicillin-clavulanate and cefuroxime. No morphological\nor functional urinary tract abnormalities  were  detected.\nEc870 harbored the ESBL gene bla CTX-M-14 ,  which  explains\nthe resistant phenotype to ampicillin, cefazolin,  cefuroxime\nand  ceftriaxone, and the  fosfomycin  resistance  gene  fosA3\nresponsible for  fosfomycin  resistance  (Table  2).  The  isolate\nbelonged to  phylogenetic  group  D  and  ST69.  Two  plasmids\nof approximately  45  kb  and  150  kb  in  size,  incompatibility\ngroups F,  FII,  FIA,  FIB  and  N,  and  addiction  systems  vagCD ,\nhok/sok, ccdAB ,  were  detected  in  Ec870.  Conjugation  assays\nwere positive,  and  bla CTX-M-14 /fosA3  were  co-transferred  and\ndetected in  transconjugants  (TcEc870).  TcE870  presented\nonly a  45  kb  plasmid,  IncN  type.  None  of  the  toxin-antitoxin\ngenes studied  were  detected  in  transconjugants.  MIC  to  fos-\nfomycin was  256  mg/l  for  donor  and  transconjugant  strains.\nCommunity-acquired UTI  caused  by  antibiotic-resistant\nbacteria is  increasing  worldwide,  leading  to  the  need  for\nalternative antibiotic  plans.  Even  though  fosfomycin  is  an\nold antibiotic,  FT  was  introduced  in  the  last  years  for  the\ntreatment of  lower  UTI  in  children  older  than  6  years  old.\nFosfomycin susceptibility  is  not  always  tested  in  clinical\nmicrobiology laboratories,  and  scarce  data  are  available  in\nchildren.\nIn this  study,  E.  coli  was  the  predominant  etiological\nagent (89.2%)  of  UTI  in  children  aged  6- - -14  years,  followed\n122Revista  Argentina  de  Microbiolog\u00eda  54  (2022)  120- - -124\nTable 2  Phenotypic  and  genotypic  characteristics  of  fosfomycin-resistant  Ec870.\nEc870  TcEc870  E.  coli  J53-2\nSource Urine  culture \u2212  \u2212\nIsolation date  15/5/2018  \u2212  \u2212\nSequence type  69  \u2212  \u2212\nPhylogenetic group  D  \u2212  \u2212\nESBL synergy  test  (+)  (+)  \u2212\nMIC (mg/l)  by  Phoenix\nAmpicillin >16  >16  4\nAmoxicillin-clavulanate 8/4  8/4  8/4\nCefazolin >16  >16  \u22644\nCefoxitin \u22644 \u22644 \u22644\nCefuroxime >16  >16  4\nCeftriaxone \u22654  \u22654  \u22641\nMeropenem \u22640.5  \u22640.5  \u22640.5\nImipenem \u22640.25 \u22640.25 \u22640.25\nAmikacin \u22648 \u22648  \u22648\nGentamicin \u22642 \u22642 \u22642\nCipro\ufb02oxacin \u22640.125 \u22640.125 \u22640.125\nTrimethoprim-sulfamethoxazole \u22640.5/9.5 \u22640.5/9.5 \u22640.5/9.5\nNitrofurantoin \u226416 \u226416 \u226416\nFosfomycin agar dilution (mg/l) 256  256 0.125\nFosfomycin disk (mm) 12 6 28\nResistance genes blaCTX-M-14\nfosA3blaCTX-M-14\nfosA3\u2212\nPlasmids\nIncompatibility groups  IncNIncF-FII-FIA-FIBIncN \u2212\nAddiction systems  vagCD -hoksok -\nccdAB(\u2212)  \u2212\nSize 45  kb\n150 kb45 kb  \u2212\nSusceptibility  test  results,  resistance  genes,  and  plasmid  characteristics.\nby  P.  mirabilis  (4.9%)  and  K.  pneumoniae  (2.5%).  The  dis-\ntribution of  the  etiological  agents  in  the  same  age  group  in\nSpain is  similar  to  that  reported  here14.\nWith regard  to  antibiotic  susceptibility,  97.9%  were  sus-\nceptible to  fosfomycin  (resistance  was  detected  in  \ufb01ve  S.\nsaprophyticus with  natural  resistance  and  one  E.  coli  with\nacquired resistance  to  fosfomycin).  In  Spain,  susceptibility\nto fosfomycin  from  UTI  isolates  in  children  aged  5- - -15  years\nwas 88%,  most  of  the  resistant  isolates  corresponded  to  K.\npneumoniae and  only  2%  of  E.  coli  isolates  were  resistant  to\nfosfomycin14.\nIn this  work,  we  identi\ufb01ed  one  conjugative  plasmid  from\nthe IncN  family  harboring  fosA3  and  bla CTX-M-14 genes.  IncN\nplasmids harboring bla CTX-M-14 were  reported  in  Salmonella\nspp. strains  in  our  country5.  However ,  this  is  not  only  the  \ufb01rst\nreport of  fosA3  but  also  the  association  of  bla CTX-M-14 /fosA3\nin an E. coli  isolate  in  Uruguay.\nAlthough E. coli ST69, harboring  bla CTX-M-9 (another  mem-\nber of the bla CTX-M-9-group along  with  bla CTX-M-14 )  has  been\npreviously detected  in  adults  in  Uruguay15,  its  isolation  in\nchildren is  novel.  Contrary  to  these  results,  commonly,  ST69\nisolates are  considered  susceptible  to  almost  all  the  antibi-\notic families7.  As  far  as  we  know,  this  is  the  \ufb01rst  detectionof  fosA3 /bla CTX-M-14 in  a  ST69  E.  coli  isolate  of  human  origin\nworldwide.\nIn this  sense,  the  occurrence  of  these  resistance  deter-\nminants in  a  conjugative  plasmid  brings  the  possibility  to\ntransfer to  other  sequence  types  with  resistance  to  more\nantibiotic families  such  as  ST1317.\nOn the  other  hand,  this  \ufb01nding  is  worrisome  due  to  the\npossible dissemination  of  these  resistance  mechanisms  to\nsusceptible strains.  Considering  this,  the  UTI  treatment  with\nsecond or  third-generation  cephalosporins  or  fosfomycin\ntromethamine could  exert  selective  pressure  for  the  occur-\nrence of  isolates  resistant  to  both  antibiotic  families,  as  such\nwas the  case  with  this  patient  who  had  received  cefuroxime\nfor the  treatment  of  previous  UTI  episodes.\nMost of  the  strains  studied  in  this  work  showed  high\nsusceptibility to  different  antibiotics,  except  ampicillin\nand trimethoprim-sulfamethoxazole in which  resistance\nexceeded 20%. In a cohort  of  children  in  Spain,  resis-\ntance rates to ampicillin,  amoxicillin-clavulanate  and\ntrimethoprim-sulfamethoxazole were  above  20%14.  Our  local\nresults showed  high  susceptibility  rates  to  amoxicillin-\nclavulanate, endorsing  its  use  for  oral  UTI  empirical\ntreatment. In  the  cohort  of  children  included  in  our  study,\n123V.  Garcia-Fulgueiras,  L.  Caiata,  I.  Bado  et  al.\nESBL  enterobacteria  were  detected  in  only  2  urine  cultures\n(0.7%), a  frequency  that  was  lower  than  that  reported  in\nFrance (0.8-10%)11and  Spain  (1.8%)14.\nThe high susceptibility to many oral  antimicrobial  agents\nin  our  setting  broadens  empirical  treatment  options.  For\nlower UTI,  amoxicillin-clavulanate  and  nitrofurantoin  could\nbe suitable  options.  Fosfomycin  shows  several  advan-\ntages for  its  use,  such  as  once-daily  dosing,  low  side\neffects, suitable  clinical  and  microbiology  results,  and  lit-\ntle effect  on  intestinal  microbiota13.  However ,  considering\nthat fosfomycin  is  active  against  ESBL  and  carbapenemase\nenterobacteria producers, its  use  is  not  recommended  when\nthere are  other  treatment options of  a  narrower  spectrum.\nAs its use increases,  active  monitoring of resistance  levels\nwill  be  necessary.\nCon\ufb02ict  of  interest\nThe authors  declare  that  they  have  no  con\ufb02icts  of  interest.\nReferences\n1.  Baquero-Artigao  F,  Del  Rosal  Rabes  T.  Fosfomycin  in  the  pedi-\natric setting:  evidence  and  potential  indications.  Rev  Esp\nQuimioter.  2019;32:55- - -61.\n2.  Cao  XL,  Shen  H,  Xu  YY ,  Xu  XJ,  Zhang  ZF ,  Cheng  L,  Chen\nJH, Arakawa  Y.  High  prevalence  of  fosfomycin  resistance  gene\nfosA3  in  blaCTX-M -harbouring  Escherichia  coli  from  urine  in  a\nChinese tertiary  hospital  during  2010- - -2014.  Epidemiol  Infect.\n2017;145:818- - -24.\n3.  Clermont  O,  Bonacorsi  S,  Bingen  E.  Rapid  and  simple  determi-\nnation of  the  Escherichia  coli  phylogenetic  group.  Appl  Environ\nMicrobiol.  2000;66:4555- - -8.\n4.  Clinical  and  Laboratory  Standards  Institute.  Performance  stan-\ndards for  antimicrobial  susceptibility  testing  28th  edition,\nDocument  M100.  Wayne,  PA:  CLSI;  2018.\n5.  Cordeiro  NF ,  Nab\u00f3n  A,  Garc\u00eda-Fulgueiras  V,  \u00c1lvez  M,  Sirok  A,\nCamou  T,  Vignoli  R.  Analysis  of  plasmid-mediated  quinolone  and\noxyimino-cephalosporin  resistance  mechanisms  in  Uruguayan\nSalmonella enterica  isolates  from  2011- - -2013.  J  Glob  Antimicrob\nResist. 2016;6:165- - -71.\n6. D\u00edez-Aguilar M, Canton  R.  New  microbiological  aspects  of  fos-\nfomycin.  Spanish  J  Chemother.  2019;32:8- - -18.\n7. Doumith M,  Day  M,  Ciesielczuk  H,  Hope  R,  Underwood  A,\nReynolds R,  Wain  J,  Livermore  DM,  Woodford  N.  Rapid  iden-\nti\ufb01cation  of  major  Escherichia  coli  sequence  types  causing\nurinary  tract  and  bloodstream  infections.  J  Clin  Microbiol.\n2015;53:160- - -6.\n8.  Falagas  ME,  Vouloumanou  EK,  Samonis  G,  Vardakas  KZ.  Fos-\nfomycin.  Clin  Microbiol  Rev.  2016;29:321- - -47.9.  Garcia-Fulgueiras  V,  Araujo  L,  Bado  I,  Cordeiro  NF ,  Mota  MI,\nLaguna G,  Algorta  G,  Vignoli  R.  Allodemic  distribution  of\nplasmids  co-harbouring  blaCTX-M-15 /aac(6/prime)-Ib-cr /qnrB  in  Kleb-\nsiella pneumoniae  is  the  main  source  of  extended-spectrum\n/H9252-lactamases  in  Uruguay\u2019s  paediatric  hospital.  J  Glob  Antimi-\ncrob Resist.  2017;9:68- - -73.\n10.  Garcia-Fulgueiras  V,  Zapata  Y,  Papa-Ezdra  R,  \u00c1vila  P,  Caiata  L,\nSeija  V,  Rojas  Rodriguez  AE,  Magallanes  C,  M\u00e1rquez  Villalba  C,\nVignoli R. First  characterization  of K. pneumoniae  ST11  clin-\nical isolates harboring blaKPC-3 in  Latin  America.  Rev  Argent\nMicrobiol. 2019;52:211- - -6.\n11.  Madhi  F,  Jung  C,  Timsit  S,  Levy  C,  Biscardi  S,  Lorrot  M,  Grim-\nprel E,  Hees  L,  Craiu  I,  Galerne  A,  Dubos  F,  Cixous  E,  Hentgen\nV,  B\u00e9chet  S,  Bonacorsi  S,  Cohen  R,  Angoulvant  F,  Ferroni  A,\nGaschignard J,  Desmarest  M,  Aberrane  S,  Brussieux  M,  Vu-\nThien  H,  Moissenet  D,  Gillet  Y,  Beraud  L,  Zenkhri  F,  Cuzon  G,\nDe-Pontual L,  Poilane  I,  Martinot  A,  Dessein  R,  Vachee  A,  Dom-\nmergues  MA,  Pangon  B,  Gajdos  V,  Cochez  M,  Doucet-Populaire  F,\nDanekova  N,  Cojocaru  B,  Branger  C,  Soussan-Banini  V,  Sivadon-\nTardy  V,  Launay  E,  Gras-Leguen  C,  Caillon  J,  Pinquier  D,  Boyer\nS, Georget  E,  Chace  A,  Breuil  J,  Orzechowski  C,  Andriantahina\nI,  Sanchez  X,  Garrec  H,  Breant  I,  Pitsch  A,  Traore  P,  Tahiri  C,\nFarrugia C,  Ducrocq  S,  Farges-Berth  A,  Haas  H,  Starck  B,  Vig-\nnaud  O,  Fiacre  A,  Belgaid  A,  Labbe  F,  Decobert  M,  Adam  MN.\nFebrile urinary-tract infection due to extended-spectrum beta-\nlactamase-producing\n Enterobacteriaceae in children: a  French\nprospective multicenter  study.  PLoS  One.  2018;13:1- - -14.\n12.  Pi\u02dcneiro  P\u00e9rez  R,  Mart\u00ednez  Campos  L,  Cilleruelo  Ortega  MJ,\nPi\u02dcneiro P\u00e9rez  R,  Jos\u00e9  Cilleruelo  Ortega  M,  Ares  \u00c1lvarez  J,\nBaquero-Artigao  F,  Carlos  Silva  Rico  J,  Velasco  Zu\u02dcniga  R,\nMart\u00ednez  Campos  L,  Carazo  Gallego  B,  Jos\u00e9  Conejo  Fern\u00e1ndez  A,\nCalvo Rey  C,  Alfayate  Migu\u00e9lez  S,  Berghezan  Su\u00e1rez  A,  Garc\u00eda\nVera  C,  Jos\u00e9  Garc\u00eda  Garc\u00eda  J,  Herreros  Fern\u00e1ndez  M,  Rodrigo\nGonzalo de  Liria  C.  Recomendaciones  sobre  el  diagn\u00f3stico  y\ntratamiento  de  la  infecci\u00f3n  urinaria,  respuesta  de  los  autores.\nAn  Pediatr\u00eda.  2020;92:184- - -6.\n13.  Robino  L,  Notejane  M,  Casuriaga  A,  Galain  B,  Garcia  C,  M\u00e1s\nM, Giachetto  G.  Fosfomicina  en  el  tratamiento  de  la  infecci\u00f3n\nurinaria  baja  en  ni\u02dcnos  mayores  de  6  a\u02dcnos  Evoluci\u00f3n  cl\u00ednico-\nmicrobiol\u00f3gica. Arch  Pediatr  Urug.  2020;91:21- - -30.\n14.  Rodr\u00edguez-Lozano  J,  de  Malet  A,  Cano  ME,  de  la  Rubia\nL,  Wallmann  R,  Mart\u00ednez-Mart\u00ednez  L,  Calvo  J.  Antimicro-\nbial susceptibility  of  microorganisms  that  cause  urinary  tract\ninfections  in  pediatric  patients.  Enferm  Infecc  Microbiol  Clin.\n2018;36:417- - -22.\n15.  Vignoli  R,  Garc\u00eda-Fulgueiras  V,  Cordeiro  NF ,  Bado  I,  Seija  V,\nAguerrebere P,  Laguna  G,  Ara\u00fajo  L,  Bazet  C,  Gutkind  G,\nChabalgoity  A.  Extended-spectrum  /H9252-lactamases,  transferable\nquinolone resistance,  and  virulotyping  in  extra-intestinal  E.  coli\nin  Uruguay.  J  Infect  Dev  Ctries.  2016;10:43- - -52.\n124", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}